ABSTRACT
INTRODUCTION
Systemic sclerosis (SSc) is a rare autoimmune disease characterized by endothelial dysfunction and tissue fi brosis. It is a diffuse connective tissue disease that can affect several organic systems, especially the digestive and respiratory systems. Systemic sclerosis has two presentation forms, limited and diffuse, which are differentiated based on the extension of skin involvement. 1 Its major characteristics are excessive collagen deposition, vascular lesions, and changes in cellular and humoral immunity. 2 There is evidence that certain genetic characteristics favor the progression of chronic infl ammation to fi brosis. Participation of the immune system has been suggested due to the presence of mononuclear cellular infi ltrates in lesions, abnormalities in T helper cells and in monocyte function,
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The NK cells have receptors, denominated 'killer immunoglobulin-like receptors' (KIR), which belong to the family of the immunoglobulins present on cell surface. According to their functional groups, those receptors are classifi ed as inhibitory (prevent target cell lysis) or activatory (cause target cell lysis). 5 The inhibitory receptor recognizes the specifi c HLA class I antigen, preventing the attack of NK cells against normal cells; conversely, the activatory receptor is triggered when inhibitory KIR receptors do not recognize the target cell, activating NK cells for destruction. 6 The ability to attack 'self' cells that do not express HLA-I is known as 'missing self-recognition'. That hypothesis has been supported by several independent observations, demonstrating that HLA antigens really protect cells against lysis by NK cells, providing negative signs that inhibit the activity of NK cells. 7 Theoretically, any inhibitory ligand combination KIR-HLA should be able to neutralize activation. The function of NK cells is regulated by positive and negative signals transmitted by pairs of activatory and inhibitory receptors. In vivo, NK cells are controlled by inhibitory receptors for self HLA-I ligands. 8 Thus, effector functions occur only when activation signals can surpass inhibitory signaling. That is obtained through either the predominance of the activation of receptor-ligand interactions or lack of the inhibitory ligand of the receptor. 9 A novel model has been recently proposed by Nelson et al., 10 predicting that, depending on the genotype, individuals could be classifi ed into one of three groups, according to the activity characteristics of their NK cells: 1) mainly controlled by inhibitory receptors (major inhibition); 2) controlled equally by inhibitory and activating receptors (relatively neutral); or 3) mainly controlled by activating receptors (major activation). Similarly, individuals lacking ligands for inhibitory receptors (such as homozygous for HLA-Cw group 1 or 2 ligands) will have fewer NK cells under inhibitory control than individuals with all ligands present. So far, only two studies have assessed the activity of NK cells according to that novel model -one in diabetes 11 and the other in psoriasis. 12 Because of the scarcity of studies on the subject, this study aimed at assessing the activity of NK cells in a group of patients with SSc as compared to a control group.
PATIENTS AND METHODS
All participants were instructed about this research. They provided written informed consent, and their decision did not affect the physician-patient relationship. This study was approved by the Ethics Committee of the Hospital de Clínicas de Porto Alegre (HCPA).
Patients
This study included 110 patients with SSc originating from the Rheumatology Outpatient Clinic of the HCPA. All patients had been diagnosed according to either the 1987 American College of Rheumatology criteria 13 or the LeRoy and Medsger's criteria for the classifi cation of early SSc. 14 Patients with overlap syndromes with other diffuse connective tissue diseases (except for Sjögren's syndrome) were excluded from the study.
Controls
The control group comprised 115 unrelated individuals, originating from the Immunology Service of the HCPA, who voluntarily registered to donate bone marrow (REDOME). Individuals with chronic and acute diseases were excluded from the sample, as were those with a family history of genetic disorders (X chromosome-linked diseases, autosomal diseases or chromosomal abnormalities).
Immunogenetic study
The DNA samples were extracted according to the salting out 15 method and amplifi ed according to the polymerase chain reaction (PCR) technique. The sequence of primers for PCR has been described by Gómez-Lozano et al. 16 The following mixture was used for DNA amplifi cation: 1 μL of 10x buffer; 50 nM of MgCl 2 ; 25 mM of dNTPs; 0.5 U taq polymerase; 10 ηg of DNA; 100 nm of internal control; and 500 mM of specifi c primer. The initial temperature for amplifi cation was 94ºC for 3 minutes. Then, there were 4 cycles of 15 seconds at 94ºC, 15 seconds at 65ºC, and 30 seconds at 72ºC. Then, there were 21 cycles of 15 seconds at 94ºC, 15 seconds at 60ºC, and 30 seconds at 72ºC. To fi nish, 5 cycles of 15 seconds at 94ºC, 60 seconds at 55ºC, and 120 seconds at 72ºC. The product was maintained for 420 seconds at 72ºC.
The PCR product was analyzed by use of 1% agarose gel electrophoresis (p/v) and tris-acetate-EDTA (TAE) buffer. Electrophoresis ran for 20 minutes at 200 V and room temperature. After electrophoresis was complete, the gel was stained with ethidium bromide, and the bands visualized and photographed under ultraviolet light.
Statistical analysis
The model that predicts the activity of NK cells was applied as follows: a) KIR2DS1 and/or KIR2DS2 with homozygous HLACw for group 1 or 2 (combination of susceptibility -excessive activation); b) KIR2DS1 and/or KIR2DS2 with heterozygous HLA-Cw group; c) lack of KIR2DS1 or KIR2DS2 with homozygous HLA-Cw group (relatively neutral combination -balance);
Rev Bras Reumatol 2013;53(1):66-74 and d) lack of KIR2DS1 or KIR2DS2 with heterozygous HLACw group (combination of protection -excessive inhibition). The results were assessed by use of Pearson's chi-square test and the SPSS 16.0 software. Statistical signifi cance was adopted as a P value ≤ 0.05. Table 1 shows the patients' genetic profi le. Presence of all KIR genes tends to provide protection against the development of SSc. That genetic profi le was evidenced in 1.77% of the patients with SSc as compared to 13.9% of the controls (P < 0.001). The other genetic profi les showed no signifi cant difference.
RESULTS
Activation of NK cells can be predicted by the possible combination of receptor activation or inhibition with the HLA-C molecule. That indicates that, depending on the genotype, an individual can have more over-active or balanced or over-inhibited NK cells. In this study, patients with SSc had excessive activation as compared with controls (Table 2) . Of the 110 patients with SSc, 34 (29.6%) had over-active NK cells as compared with 22 of 115 (19.1%) controls. Analyzing excessive inhibition in each group, the control group had that profi le more often.
Previous studies have evidenced that the presence of the inhibitory KIR2DL2 gene might be related to protection against the development of SSc. To test that hypothesis, we stratifi ed the patients according to the presence or absence of that gene (Table  3) . Considering only 2DL2-positive patients, we observed that the control group had excessive inhibition (34.7%) as compared to patients with the disease (10.9%), with a statistically signifi cant difference (< 0.001). Analyzing balanced or over-active NK cells in the presence of the 2DL2 gene, no statistically signifi cant difference was observed. Patients with SSc had 10.2% of excessive activation and 10% of balance, similarly to controls, who had 16.5% and 11.3%, respectively. Assessing patients who lack the KIR2DL2 gene, different results were found. The frequency of excessive inhibition in patients (29.1%) is similar to that of the control group (26.1%). Thus, the balanced or excessively activated state of NK cells is less frequent in healthy individuals (2.6% and 6.1%, respectively) as compared to patients with SSc (20.9% and 20.9%, respectively).
DISCUSSION
Systemic sclerosis is a complex multifactorial disease. The most accepted hypothesis for its pathogenesis is that immune system activation is triggered by the interaction between environmental factors and genetic predisposition. 17 Some genetic factors can infl uence the susceptibility to the development of SSc. Family history is the major risk factor identifi ed; however, the absolute risk for each family member is low (< 1%). The relative risk for fi rst-degree relatives ranges from 10 to 16, and, for monozygous twins, from 10 to 27. 18 Several studies have suggested that genetic susceptibility alone is not enough to induce disease.
In our study, 9.73% of the patients with SSc had activating 2DS2 and inhibitory 2DL2, and lack of activating 2DS1, 2DS3 and 3DS1, as compared to 13.9% of the control group, and, thus, protection might also be provided by that profi le. The profi le 'absence of inhibitory 2DL2 and of activating 2DS1, 2DS2 and 2DS3' was found only in patients with SSc (9.73%). Conversely, the profi le 'presence of inhibitory 2DL2 and absence of the activating genes' was only found in the control group (6.1%), and the presence of all genes (including the activating 2DS2 and inhibitory 2DL2) was more often found in the control group than in patients with SSc. Such data show the importance of inhibitory 2DL2 for the development of SSc, and are in accordance with a previous study that showed an increase in the frequency of activating KIR2DS2 in the absence of inhibitory KIR2DL2 in patients with SSc. 19 Recently, using data of the same patients involved in the present study, we have reported a protective effect of the inhibitory 2DL2 gene against the development of SSc. 20 That combination of KIR genes has also been observed in the pathogenesis of other rheumatic diseases. In rheumatoid arthritis, the presence of KIR2DS2 has been related to vasculitis; 21 in psoriatic arthritis, KIR2DS2 in the absence of KIR2DL2 ligands has been associated with a higher risk of developing that disease. 11 In addition, the involvement of the KIR2DS2+/ KIR2DL2− combination in the pathogenesis of Sjögren's syndrome has been suggested. 22 Recent studies have suggested that HLA-I genes might play a role in susceptibility to autoimmune diseases and their expression, such as rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus, through the interaction with KIR receptors. Based on the idea that an activating KIR, such as KIR2DS2, can favor the development of SSc in the absence of the ligand for any KIR2DL1 or KIR2DL2/3 (that is, homozygous for a group of HLA-Cw ligands), the novel model proposed by Nelson et al. 10 was used. That is in accordance with our understanding of KIR expression and function, and has a more robust statistical support for the role played by KIR in susceptibility to SSc than that of the previous model.
Previous studies associating the KIR genes in SSc have evidenced important results regarding susceptibility to that disease. However, no previous study has assessed the activity profi le of NK cells in patients and controls -genes were assessed in isolation only. Our study showed that healthy individuals have excessive inhibition as compared to patients with SSc (P < 0.001). That is in accordance with a study performed with patients with diabetes, 23 in which excessive inhibition was found in controls (25.71%) as compared to patients (1.02%). However, another study assessing that model in patients with psoriasis has reported no statistical difference between patients and controls (P = 0.822). 12 Stratifying patients according to the gene associated with SSc (KIR2DL2), we found excessive inhibition in KIR2DL2-positive controls (P < 0.001). When that gene was absent, there was prevalence of excessive activation (P < 0.001) and balance (P = 0.001) in patients with SSc, suggesting an important role of that gene in the development of SSc. Such observations further corroborate the hypothesis of a dominant protection provided by some inhibitory KIR genes.
CONCLUSION
Imbalance between the number of activating/inhibitory KIR genes seems to play an important role in susceptibility to and protection against SSc. When certain models are used in data analysis, the interaction between KIR/HLA-C genes might indicate the role of NK cells in the pathology of SSc. Additional levels of variations, such as allelic polymorphisms, require further investigation, and new studies on the association of KIR genes with other autoimmune disorders are necessary. The results suggest that experiences with the function of NK cells can provide more information. 
